Back to Search
Start Over
[Intravitreal bevacizumab in the treatment of idiopathic juxtafoveal telangiectasis type I].
- Source :
-
Archivos de la Sociedad Espanola de Oftalmologia [Arch Soc Esp Oftalmol] 2014 Jul; Vol. 89 (7), pp. 269-71. Date of Electronic Publication: 2013 Apr 10. - Publication Year :
- 2014
-
Abstract
- Clinical Case: We report a case of a 42 year-old male with a macular edema due to idiopathic juxtafoveal retinal telangiectasis type i, treated with 3 sequential injections of intravitreal bevacizumab (1.25 mg in 0.05 ml). Anatomical improvements were observed after one year of follow up.<br />Discussion: There is currently no general consensus regarding the treatment of unilateral idiopathic juxtafoveal telangiectasis. The therapeutic options are, grid laser photocoagulation, intravitreal triamcinolone, verteporfin photodynamic therapy, or anti-VEGF. Visual acuity and anatomical improvements were observed in this case after intravitreal bevacizumab. Thus, intravitreal bevacizumab seems to be effective to treat macular edema in idiopathic juxtafoveal telangiectasis type i.<br /> (Copyright © 2011 Sociedad Española de Oftalmología. Published by Elsevier Espana. All rights reserved.)
Details
- Language :
- Spanish; Castilian
- ISSN :
- 1989-7286
- Volume :
- 89
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Archivos de la Sociedad Espanola de Oftalmologia
- Publication Type :
- Academic Journal
- Accession number :
- 24269459
- Full Text :
- https://doi.org/10.1016/j.oftal.2013.01.006